These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8399826)

  • 1. A peptide enhancement strategy in Alzheimer's disease: pilot study with TRH-physostigmine infusions.
    Mellow AM; Aronson SM; Giordani B; Berent S
    Biol Psychiatry; 1993 Aug; 34(4):271-3. PubMed ID: 8399826
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease.
    Mellow AM; Sunderland T; Cohen RM; Lawlor BA; Hill JL; Newhouse PA; Cohen MR; Murphy DL
    Psychopharmacology (Berl); 1989; 98(3):403-7. PubMed ID: 2501817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of clonidine plus physostigmine in Alzheimer's disease.
    Bierer LM; Aisen PS; Davidson M; Ryan TM; Schmeidler J; Davis KL
    Dementia; 1994; 5(5):243-6. PubMed ID: 7951680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
    Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
    J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
    Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
    J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease.
    Bierer LM; Aisen PS; Davidson M; Ryan TM; Stern RG; Schmeidler J; Davis KL
    Alzheimer Dis Assoc Disord; 1993; 7(2):98-104. PubMed ID: 8347333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drug interventions in Alzheimer's disease.
    Stern GM
    Curr Opin Neurol Neurosurg; 1992 Feb; 5(1):100-3. PubMed ID: 1623227
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
    Gustafson L; Edvinsson L; Dahlgren N; Hagberg B; Risberg J; Rosén I; Fernö H
    Psychopharmacology (Berl); 1987; 93(1):31-5. PubMed ID: 3114812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of low-dose TRH on cognitive deficits in the ECT postictal state.
    Khan A; Mirolo MH; Claypoole K; Bhang J; Cox G; Horita A; Tucker G
    Am J Psychiatry; 1994 Nov; 151(11):1694-6. PubMed ID: 7943463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.
    Davidson M; Bierer LM; Kaminsky R; Ryan TM; Davis KL
    Alzheimer Dis Assoc Disord; 1989; 3(4):224-7. PubMed ID: 2688700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
    van Dyck CH; Newhouse P; Falk WE; Mattes JA
    Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotropin-releasing hormone (TRH) and Alzheimer's disease.
    Peabody CA; Deblois TE; Tinklenberg JR
    Am J Psychiatry; 1986 Feb; 143(2):262-3. PubMed ID: 3080909
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
    Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
    Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward an effective treatment of Alzheimer's disease.
    Blass JP; Weksler ME
    Ann Intern Med; 1983 Feb; 98(2):251-3. PubMed ID: 6824261
    [No Abstract]   [Full Text] [Related]  

  • 18. Physostigmine-induced myoclonus in Alzheimer's disease.
    Mayeux R; Albert M; Jenike M
    Neurology; 1987 Feb; 37(2):345-6. PubMed ID: 3808321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer's disease.
    Molchan SE; Vitiello B; Minichiello M; Sunderland T
    Arch Gen Psychiatry; 1991 Dec; 48(12):1113-4. PubMed ID: 1845230
    [No Abstract]   [Full Text] [Related]  

  • 20. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.
    Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F
    Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.